Based on this revision of the GHG emission reduction target, Terumo has applied to the Science Based Targets initiative (SBTi) for an updated certificate to the "1.5°C target" which is in line with a level to limit the temperature rise to 1.5°C above pre-industrial levels. Terumo received an approval by SBTi in March 2020 for the previous target that commits to pursue global warming prevention efforts of well-below 2°C above pre-industrial levels.
Terumo has also publicly declared its support for the Task Force on Climate-related Financial Disclosures (TCFD) and its recommendations, which was established by the Financial Stability Board (FSB).
Under the Group's corporate mission of "Contributing to Society through Healthcare", Terumo has strived to advance healthcare and enhance patients' quality of life. In addition, Terumo has established the Terumo Group Sustainability Policy in 2021 to solidly realize its Group mission. To reduce the environmental impact of Terumo's business is a part of the sustainability priorities listed in the Policy. By ambitiously committing to achieve carbon neutrality, Terumo Group will work towards shrinking the global issue of climate change.
- * Carbon neutrality means having a balance between emitting carbon and absorbing carbon.
Terumo Group's target of GHG emission reduction
- ・Reduce absolute GHG emissions 50% by 2030 from a 2018 base year
- ・Increase a ratio of renewable electricity use up to 50% by 2030
- ・Achieve carbon neutrality by 2040
・Reduce GHG emissions 60% per unit of revenue by 2030 from a 2018 base year
Reference: Reducing Environmental Footprint
TCFD is the Task Force on Climate Related Financial Information Disclosure, which was established by the Financial Stability Board (FSB) at the request of the G20 to consider how to deal with climate-related information disclosure and financial institutions. In June 2017, TCFD had encouraged companies and organizations to voluntarily capture and disclose information on the financial implications of climate-related risks and opportunities.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.